A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913

BACKGROUND: This phase II study was designed to determine the efficacy of the mammalian target of rapamycin (mTOR) inhibitor everolimus administered daily with conventional radiation therapy and chemotherapy in patients with newly diagnosed glioblastoma. METHODS: Patients were randomized to radiatio...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Chinnaiyan, Prakash, Won, Minhee, Wen, Patrick Y, Rojiani, Amyn M, Werner-Wasik, Maria, Shih, Helen A, Ashby, Lynn S, Michael Yu, Hsiang-Hsuan, Stieber, Volker W, Malone, Shawn C, Fiveash, John B, Mohile, Nimish A, Ahluwalia, Manmeet S, Wendland, Merideth M, Stella, Philip J, Kee, Andrew Y, Mehta, Minesh P
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Clinical Investigations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5892159/
https://ncbi.nlm.nih.gov/pubmed/29126203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox209
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados